Literature DB >> 11774169

Vitronectin in the cirrhotic liver: an immunomarker of mature fibrosis.

G K Koukoulis1, J Shen, I Virtanen, V E Gould.   

Abstract

Vitronectin (Vn) is a multifunctional plasma glycoprotein produced by hepatocytes. Vn has been studied extensively as a cell adhesion molecule. However, its localization in the hepatic extracellular matrix has received relatively little attention. Cryosections of 5 normal liver samples and of 20 specimens showing posthepatitic cirrhosis were stained by the avidin-biotin complex method with a well-characterized monoclonal antibody to Vn. The extent and intensity of immunostaining were assessed semiquantitatively (0, no staining; 1+, weak focal staining; 2+, strong focal staining; 3+, strong diffuse staining). Paraffin sections from the same samples were stained with Masson trichrome (MT) and Shikata orcein (Or) methods. Frozen samples from selected cases were analyzed by Western blotting. In the normal liver, 3+ staining was limited to portal vessels. The portal tract connective tissue showed minimal staining (0 to 1+). Cirrhotic septa showed strong staining (2+). Septa lacking significant inflammation and composed of dense connective tissue, as indicated by MT and Or stains, showed the strongest Vn reactions (3+). Immunoblotting data strongly correlated with Vn increase in cirrhotic livers. Vn immunoreactivity is markedly increased in the cirrhotic liver matrix, regardless of the documented decrease in plasma Vn. Binding to collagen, elastin, and proteoglycans is the current favored mechanism of Vn deposition in tissues. Previous studies in cirrhotic patients showed increased affinity of plasma Vn to collagen. Vn is also increased in aged skin, associated with dermal elastic fibers. In other tissues, Vn deposition reflects chronicity of injury. Therefore, Vn immunoreactivity in liver can be considered a marker of fibrosis, especially of chronic/mature fibrosis, paralleling previous observations on enhanced orcein staining of cirrhotic septa. Immunolabeling of biopsy specimens with Vn and tenascin, a marker of ongoing remodeling or recently formed fibrous tissue, could be diagnostically helpful. Copyright 2001 by W.B. Saunders Company

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11774169     DOI: 10.1053/hupa.2001.29675

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  24 in total

1.  Vitronectin accumulates in the interstitium but minimally impacts fibrogenesis in experimental chronic kidney disease.

Authors:  Jesús M López-Guisa; Allen C Rassa; Xiaohe Cai; Sarah J Collins; Allison A Eddy
Journal:  Am J Physiol Renal Physiol       Date:  2011-01-26

2.  Clinical Utility of Biomarkers of Liver Fibrosis.

Authors:  Keyur Patel; Don C Rockey
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-01

3.  Vitronectin deficiency attenuates hepatic fibrosis in a non-alcoholic steatohepatitis-induced mouse model.

Authors:  Momoka Hayashida; Kei Hashimoto; Tomoko Ishikawa; Yasunori Miyamoto
Journal:  Int J Exp Pathol       Date:  2019-03-18       Impact factor: 1.925

4.  Inhibition of αvβ5 Integrin Attenuates Vascular Permeability and Protects against Renal Ischemia-Reperfusion Injury.

Authors:  Amy McCurley; Stella Alimperti; Silvia B Campos-Bilderback; Ruben M Sandoval; Jenna E Calvino; Taylor L Reynolds; Catherine Quigley; Joshua W Mugford; William J Polacheck; Ivan G Gomez; Jennifer Dovey; Graham Marsh; Angela Huang; Fang Qian; Paul H Weinreb; Brian M Dolinski; Shaun Moore; Jeremy S Duffield; Christopher S Chen; Bruce A Molitoris; Shelia M Violette; Michael A Crackower
Journal:  J Am Soc Nephrol       Date:  2017-01-06       Impact factor: 10.121

5.  The hepatic "matrisome" responds dynamically to injury: Characterization of transitional changes to the extracellular matrix in mice.

Authors:  Veronica L Massey; Christine E Dolin; Lauren G Poole; Shanice V Hudson; Deanna L Siow; Guy N Brock; Michael L Merchant; Daniel W Wilkey; Gavin E Arteel
Journal:  Hepatology       Date:  2016-12-30       Impact factor: 17.425

6.  Validation of the vitronectin knockout mouse as a model for studying myocardial infarction: Vitronectin appears to influence left ventricular remodelling following myocardial infarction.

Authors:  Gordon E Pate; Hubert P Walinski; Lubos Bohunek; Thomas J Podor
Journal:  Exp Clin Cardiol       Date:  2013

7.  Plasminogen activator-1 overexpression decreases experimental postthrombotic vein wall fibrosis by a non-vitronectin-dependent mechanism.

Authors:  A T Obi; J A Diaz; N L Ballard-Lipka; K J Roelofs; D M Farris; D A Lawrence; T W Wakefield; P K Henke
Journal:  J Thromb Haemost       Date:  2014-07-23       Impact factor: 5.824

Review 8.  It's all about the spaces between cells: role of extracellular matrix in liver fibrosis.

Authors:  Amit Khurana; Nilofer Sayed; Prince Allawadhi; Ralf Weiskirchen
Journal:  Ann Transl Med       Date:  2021-04

9.  Interaction of late apoptotic and necrotic cells with vitronectin.

Authors:  Ondrej Stepanek; Tomas Brdicka; Pavla Angelisova; Ondrej Horvath; Jiri Spicka; Petr Stockbauer; Petr Man; Vaclav Horejsi
Journal:  PLoS One       Date:  2011-05-04       Impact factor: 3.240

10.  Differences in the degree of cerulein-induced chronic pancreatitis in C57BL/6 mouse substrains lead to new insights in identification of potential risk factors in the development of chronic pancreatitis.

Authors:  Barbara Ulmasov; Kiyoko Oshima; Michael G Rodriguez; Roger D Cox; Brent A Neuschwander-Tetri
Journal:  Am J Pathol       Date:  2013-07-08       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.